NCT03640481 2024-12-12Efficacy and Safety of KD025 in Subjects With cGVHD After At Least 2 Prior Lines of Systemic TherapySanofiPhase 2 Terminated159 enrolled 25 charts 1 FDA
NCT01357655 2017-03-14Phase 2 Dasatinib Combo With Smoothened (SMO) Antagonist (BMS-833923)Bristol-Myers SquibbPhase 2 Terminated70 enrolled 8 charts
NCT01600053 2016-12-15Revlimid® as Consolidation Treatment Chronic Lymphocytic LeukemiaUniversity of California, San DiegoPhase 2 Terminated11 enrolled 4 charts